General Information of Drug (ID: DMRJ30G)

Drug Name
PMID25522065-Compound-10 Drug Info
Cross-matching ID
TTD Drug ID
DMRJ30G

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-830216 DMCW71N Obesity 5B81 Phase 1 [2]
AZD1979 DMQ1OX4 Obesity 5B81 Phase 1 [3]
PMID25522065-Compound-27 DMXN4KB N. A. N. A. Patented [1]
PMID25522065-Compound-29 DMBNAK9 N. A. N. A. Patented [1]
PMID25522065-Compound-34 DMZDIRQ N. A. N. A. Patented [1]
PMID25522065-Compound-39 DM5YMQH N. A. N. A. Patented [1]
PMID25522065-Compound-40 DMCIQ01 N. A. N. A. Patented [1]
PMID25522065-Compound-11 DM410Z6 N. A. N. A. Patented [1]
PMID25522065-Compound-50 DMBWA0V N. A. N. A. Patented [1]
PMID25522065-Compound-12 DMVKO9C N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanin-concentrating hormone receptor 1 (MCHR1) TTX4RTB MCHR1_HUMAN Antagonist [1]

References

1 Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
2 2011 Pipeline of Bristol-Myers Squibb.
3 Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc